<th id="hta7t"><sup id="hta7t"></sup></th>

<th id="hta7t"><sup id="hta7t"></sup></th>

    <th id="hta7t"><video id="hta7t"></video></th>
  1. <th id="hta7t"><option id="hta7t"></option></th><object id="hta7t"></object>
    1. <code id="hta7t"></code>
    2. <output id="hta7t"></output>

      <code id="hta7t"><em id="hta7t"></em></code>

      揚子江藥業集團持續強化藥品企業質量意識保障消費者用藥安全

      發布時間:

      2022-11-16

      作者:


      本報訊 (李吟男)日前,揚子江藥業集團召開專題會議,組織集團及各子公司生產、質量、研發、供應部門負責人集中學習討論,貫徹黨中央、國務院關于****疫苗事件會議精神,傳達江蘇泰州市藥品安全監管會議精神,進一步提高藥品生產企業的質量意識。
       
      揚子江藥業集團總經理助理梁元太說,****疫苗事件暴露出相關單位在落實藥品安全方面的嚴重失職,特別存在重大風險隱患信息不報告、應急處置不力等問題。對此,黨中央、國務院要求抓緊完善相關法律法規,健全最嚴格的藥品監管體系,完善疫苗全鏈條監管和電子追溯等制度,堵塞監管漏洞,推動國產疫苗技術升級,切實保障消費者用藥安全。
       
      據悉,**疫苗事件發生后,泰州市也召開了進一步加強藥品安全監管工作會議。泰州市副市長王學鋒要求各部門深入排查整改藥品安全源頭性、區域性風險隱患,從源頭上嚴防嚴控藥品生產、流通各環節安全風險,確保管理責任到位,監督職責到位,應對處置舉措到位,努力保障人民群眾用藥安全。
       
      揚子江藥業集團執行總經理梁宏指出,生產企業是藥品質量責任的主體,對企業的要求是依法依規和守住道德底線。****疫苗事件為所有制藥企業及藥品監管部門敲響了警鐘,并再一次驗證了質量是企業立身之本,管控藥品生產的全周期,確保藥品安全有效、質量可控,將是揚子江藥業集團對藥品質量的承諾。梁宏要求集團各部門結合即將開展的第40次“質量月”活動,進一步探討如何加強質量管理,并提出具體的改進措施。在第40次“質量月”活動驗收時,揚子江藥業集團將組織一次全面的大檢查,特別要集中現場檢查,確保各生產環節合規合法。
       
      長期以來,揚子江藥業集團憑借高效優質的產品,在市場上贏得了良好口碑,獲得了中國質量獎提名獎、全球卓越績效獎、質量標桿企業等榮譽。作為藥品生產企業,揚子江人從未掉以輕心,時刻反省自危,時刻牢記“任何困難都不能把我們打倒,唯有質量”的質量精神,始終踐行“為父母制藥,為親人制藥”的質量文化,堅持質量零缺陷,誠信生產,為集團發展保駕護航。
      揚子江藥業 青島日水 圖
      《中國國門時報》
       
      Yangzi Pharmaceutical Group continues to strengthen quality awareness of pharmaceutical companies to protect consumers' medication safety
      A few days ago, Yangzijiang Pharmaceutical Group held a special meeting to organize the leaders of the production, quality, research and development, and supply departments of the group and its subsidiaries to study and discuss, to implement the spirit of the CPC Central Committee and the State Council meeting on the ** vaccine incident, and to convey the spirit of the Jiangsu Taizhou Drug Safety Supervision Conference. Improve the quality awareness of pharmaceutical manufacturers.
      Liang Yuantai, assistant general manager of Yangzijiang Pharmaceutical Group, said that the **** vaccine incident exposed serious dereliction of duty in the implementation of drug safety by relevant units, especially the lack of reporting of information on major risks and inadequate emergency response. In this regard, the Party Central Committee and the State Council require that relevant laws and regulations be improved, the most stringent drug regulatory system be perfected, the whole chain of vaccine supervision and electronic traceability be improved, loopholes in supervision be plugged, domestic vaccine technology upgraded, and consumers'medication safety be effectively guaranteed.
      It is reported that after the ** vaccine incident, Taizhou City also held a meeting to further strengthen drug safety supervision. Wang Xuefeng, deputy mayor of Taizhou City, asked all departments to thoroughly investigate and rectify the hidden dangers of the source and regional risks of drug safety, strictly guard against and control the safety risks in all links of drug production and circulation from the source, ensure that the management responsibility is in place, supervise responsibility is in place, and deal with measures in place to ensure the safety of drug use by the people.
      Liang Hong, executive general manager of Yangzijiang Pharmaceutical Group, pointed out that the manufacturing enterprises are the main body of drug quality responsibility, and the requirement for enterprises is to abide by the law and keep the moral bottom line. **** The vaccine incident has sounded an alarm bell for all pharmaceutical enterprises and drug regulatory authorities. It has once again proved that quality is the foundation of an enterprise. It is the promise of Yangzijiang Pharmaceutical Group to control the whole cycle of drug production and ensure the safety, effectiveness and quality control of drugs. Liang Hong asked all departments of the group to further explore how to strengthen quality management and put forward specific improvement measures in the light of the forthcoming 40th "Quality Month" activity. In the 40th "Quality Month" activity acceptance, Yangzijiang Pharmaceutical Group will organize a comprehensive inspection, especially on-site inspection, to ensure that all production links comply with the law.
      For a long time, Yangzijiang Pharmaceutical Group has won a good reputation in the market by virtue of its high efficiency and high quality products, and won the awards of China Quality Award nomination, Global Excellent Performance Award, and quality benchmarking enterprises. As a pharmaceutical manufacturer, Yangzijiang people never take it lightly, always reflect on their own dangers, always keep in mind the quality spirit of "no difficulty can knock us down, only quality", always practice the quality culture of "pharmaceutical for parents, pharmaceutical for relatives", adhere to the quality of zero defect, honest production, the development of the Group to ensure the driving force Escort.
      China National times
      一本色道久久综合亚洲精品,综合久久给合久久狠狠狠97色,一本色道久久综合一区,亚洲精品人成无码中文毛片
      <th id="hta7t"><sup id="hta7t"></sup></th>

      <th id="hta7t"><sup id="hta7t"></sup></th>

        <th id="hta7t"><video id="hta7t"></video></th>
      1. <th id="hta7t"><option id="hta7t"></option></th><object id="hta7t"></object>
        1. <code id="hta7t"></code>
        2. <output id="hta7t"></output>

          <code id="hta7t"><em id="hta7t"></em></code>